Last reviewed · How we verify
JTZ-951
JTZ-951 is a selective antagonist of the apelin receptor (APJ) that modulates cardiovascular and metabolic pathways.
JTZ-951 is a selective antagonist of the apelin receptor (APJ) that modulates cardiovascular and metabolic pathways. Used for Heart failure with reduced ejection fraction (HFrEF).
At a glance
| Generic name | JTZ-951 |
|---|---|
| Also known as | enarodustat |
| Sponsor | JW Pharmaceutical |
| Drug class | Apelin receptor antagonist |
| Target | APJ (apelin receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The apelin-APJ axis plays a role in vascular function, cardiac contractility, and metabolic regulation. By blocking APJ signaling, JTZ-951 may improve cardiac function and reduce pathological remodeling in heart failure. The drug is being developed primarily for cardiovascular indications where APJ antagonism could provide therapeutic benefit.
Approved indications
- Heart failure with reduced ejection fraction (HFrEF)
Common side effects
Key clinical trials
- A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis. (PHASE3)
- Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis (PHASE1)
- Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease (PHASE1)
- Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease (PHASE1)
- Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JTZ-951 CI brief — competitive landscape report
- JTZ-951 updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI